** Recent investments by AstraZeneca AZN.L, Merck MRK.N and Royale Life Pharma underscore Philippines' position as a key manufacturer in the region, says a research report by BMI, a unit of Fitch Solutions
** The country's special economic zone offers drugmakers a reduced corporate tax rate of 20% among other advantages - BMI
** Philippines' pharmaceutical market to rise to $7.5 bln by 2029 from $6.1 bln in 2024 at a CAGR of 4.1% in U.S. dollar terms, brokerage says
** AstraZeneca earlier this month said it is setting up an R&D hub in the country, making it the Philippines' first pharmaceutical innovation hub
** However, while the domestic pharmaceutical market will grow, challenges remain, such as a gap in "both financial resources and skilled human capital necessary for advanced pharmaceutical research" - BMI
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。